One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Retained GlobalRPh text includes older CrCl-based ceilings. The retrieved RX gout table specifies lower initiation doses without band-specific maxima; the 2020 ACR guideline supports monitored titration to target, including in CKD.
What to reconcile: Do not silently blend old ceilings, new starting doses or cancer-therapy dialysis rows. Reconcile the intended gout regimen, source date and renal measure with a clinician.
Open this note and its source referencesGout initiation and cancer-associated hyperuricemia have different renal tables in the same label. The dialysis schedule belongs to the cancer indication, not a universal gout regimen.
What to reconcile: Select the indication first. An initial low gout dose is not an eGFR-specific maintenance ceiling.
Open this note and its source referencesThe guideline prefers allopurinol as first-line urate-lowering therapy, including in CKD stage 3 or worse. Start low, at 100 mg/day or less and lower in CKD; a starting dose of 50 mg/day or less may be considered. Titrate with serial serum urate toward a target below 6 mg/dL rather than maintaining an arbitrary fixed dose.
Some patients with CKD may still require more than 300 mg/day to reach target. That observation does not authorize an unmonitored escalation or specify a dialysis regimen. The recommendation distinguishes safer initiation from the individualized maintenance dose.
RDM55-professional-allopurinol-309b2b661a-C1 · Source locator: Recommendations for choice of initial ULT; low starting dose; treat-to-target and serum urate target
Full primary guideline text retrieved; selected initiation and titration recommendations summarized.
This is the dated 2020 guideline, not a claim that every subsequent guideline or trial was reviewed.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=allopurinol&s1=RDM55-professional-allopurinol-309b2b661a&h1=eafcb3c20ec284bcd0f06ec7c145dcf06f0142a2f814c401b63a8e7f8462229d